Botanical Ingredient

1-Deoxynojirimycin Safety Tips

Handling of 1-Deoxynojirimycin should only be performed by personnel trained and familiar with handling potent active pharmaceutical ingredients. Moderate to severe irritant to the skin and eyes.

References

• 1. Hypoxia modulates A431 cellular pathways association to tumor radioresistance and enhanced migration revealed by comprehensive proteomic and functional studies.
  Ren Y, Hao P, Dutta B, Cheow ES, Sim KH, Gan CS, Lim SK, Sze SK.Mol Cell Proteomics. 2012 Nov 30. [Epub ahead of print]
• 2. Intestinal alpha-glucosidase inhibitors: abdominal gas cysts.
  [No authors listed]Prescrire Int. 2012 Sep;21(130):212-3.
• 3. Anti-diabetic effect of a traditional Chinese medicine formula.
  Wang HJ, Chiang BH.Food Funct. 2012 Nov;3(11):1161-9. doi: 10.1039/c2fo30139c.
• 4. α-Geminal dihydroxymethyl piperidine and pyrrolidine iminosugars: synthesis, conformational analysis, glycosidase inhibitory activity, and molecular docking studies.
  Pawar NJ, Parihar VS, Chavan ST, Joshi R, Joshi PV, Sabharwal SG, Puranik VG, Dhavale DD.J Org Chem. 2012 Sep 21;77(18):7873-82. Epub 2012 Aug 29.
• 5. Screening α-glucosidase inhibitors from mulberry extracts via DOSY and relaxation-edited NNR.
  Shang Q, Xiang JF, Tang YL.Talanta. 2012 Aug 15;97:362-7. doi: 10.1016/j.talanta.2012.04.046. Epub 2012 May 10.
• 6. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
  Khanna R, Flanagan JJ, Feng J, Soska R, Frascella M, Pellegrino LJ, Lun Y, Guillen D, Lockhart DJ, Valenzano KJ.PLoS One. 2012;7(7):e40776. doi: 10.1371/journal.pone.0040776. Epub 2012 Jul 18.
• 7. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
  Siekierska A, De Baets G, Reumers J, Gallardo R, Rudyak S, Broersen K, Couceiro J, Van Durme J, Schymkowitz J, Rousseau F.J Biol Chem. 2012 Aug 17;287(34):28386-97. doi: 10.1074/jbc.M112.351056. Epub 2012 Jul 6.
• 8. Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
  Pérez-Poyato MS, Gordo MM, Marfa MP.Gene. 2012 Sep 10;506(1):207-10. doi: 10.1016/j.gene.2012.06.054. Epub 2012 Jun 28.
• 9. Treatable metabolic psychoses that go undetected: what Niemann-Pick type C can teach us.
  Klünemann HH, Santosh PJ, Sedel F.Int J Psychiatry Clin Pract. 2012 Sep;16(3):162-9. doi: 10.3109/13651501.2012.687451. Epub 2012 Jul 3. Review.
• 10. Scalable syntheses of both enantiomers of DNJNAc and DGJNAc from glucuronolactone: the effect of N-alkylation on hexosaminidase inhibition.
  Glawar AF, Best D, Ayers BJ, Miyauchi S, Nakagawa S, Aguilar-Moncayo M, García Fernández JM, Ortiz Mellet C, Crabtree EV, Butters TD, Wilson FX, Kato A, Fleet GW.Chemistry. 2012 Jul 23;18(30):9341-59. doi: 10.1002/chem.201200110. Epub 2012 Jun 26.
• 11. Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
  Yu W, Gill T, Wang L, Du Y, Ye H, Qu X, Guo JT, Cuconati A, Zhao K, Block TM, Xu X, Chang J.J Med Chem. 2012 Jul 12;55(13):6061-75. doi: 10.1021/jm300171v. Epub 2012 Jun 29.
• 12. Early miglustat therapy in infantile Niemann-Pick disease type C.
  Di Rocco M, Dardis A, Madeo A, Barone R, Fiumara A.Pediatr Neurol. 2012 Jul;47(1):40-3. doi: 10.1016/j.pediatrneurol.2012.04.005.
• 13. Traditional medicinal herbs and food plants have the potential to inhibit key carbohydrate hydrolyzing enzymes in vitro and reduce postprandial blood glucose peaks in vivo.
  Mahomoodally MF, Subratty AH, Gurib-Fakim A, Choudhary MI, Nahar Khan S.ScientificWorldJournal. 2012;2012:285284. doi: 10.1100/2012/285284. Epub 2012 Feb 20.
• 14. Deoxygenative olefination reaction as the key step in the syntheses of deoxy and iminosugars.
  Chang Hsu Y, Hwu JR.Chemistry. 2012 Jun 18;18(25):7686-90. doi: 10.1002/chem.201201060. Epub 2012 May 21.
• 15. Metabolic liver disease.
  McKiernan P.Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):287-90. doi: 10.1016/j.clinre.2012.03.028. Epub 2012 Apr 19.
• 16. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
  Kimura T, Suzuki J, Ichikawa M, Imagawa M, Sato S, Fujii M, Zenimaru Y, Inaba S, Takahashi S, Konoshita T, Miyamori I.Diabetes Technol Ther. 2012 Jul;14(7):545-51. doi: 10.1089/dia.2012.0015. Epub 2012 Apr 20.
• 17. Unexpected cure from cutaneous leukocytoclastic vasculitis in a patient treated with N-butyldeoxynojirimycin (miglustat) for Gaucher disease.
  Machaczka M, Klimkowska M, Hägglund H.Adv Med Sci. 2012 Jun 1;57(1):169-73. doi: 10.2478/v10039-012-0021-y.
• 18. Carboxymethylcellulose sodium improves the pharmacodynamics of 1-deoxynojirimycin by changing its absorption characteristics and pharmacokinetics in rats.
  Wang L, Peng J, Wang X, Zhu X, Cheng B, Gao J, Jiang M, Bai G, Hou Y.Pharmazie. 2012 Feb;67(2):168-73.
• 19. Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation.
  Standl E, Schnell O.Diab Vasc Dis Res. 2012 Jul;9(3):163-9. doi: 10.1177/1479164112441524. Epub 2012 Apr 16. Review.
• 20. Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C.
  Stein VM, Crooks A, Ding W, Prociuk M, O’Donnell P, Bryan C, Sikora T, Dingemanse J, Vanier MT, Walkley SU, Vite CH.J Neuropathol Exp Neurol. 2012 May;71(5):434-48. doi: 10.1097/NEN.0b013e31825414a6.

Details